{"id":"dapt-on-target","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Bleeding (major and minor)"},{"rate":"5-10","effect":"Dyspepsia"},{"rate":"3-8","effect":"Bruising"},{"rate":"1-3","effect":"Gastrointestinal hemorrhage"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DAPT combines two antiplatelet agents that work synergistically—typically aspirin (irreversible cyclooxygenase inhibitor) and a P2Y12 receptor antagonist (e.g., clopidogrel, prasugrel, or ticagrelor)—to prevent platelet activation and clot formation through complementary mechanisms. This combination is more effective than monotherapy at reducing stent thrombosis and recurrent ischemic events in cardiovascular disease.","oneSentence":"DAPT (dual antiplatelet therapy) on-target inhibits platelet aggregation through simultaneous blockade of multiple platelet activation pathways to prevent thrombotic events.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:44:11.716Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI) and stent placement"},{"name":"Secondary prevention of stent thrombosis and recurrent myocardial infarction"}]},"trialDetails":[{"nctId":"NCT07349979","phase":"NA","title":"PCI With Guideline-Directed Medical Therapy for HFpEF Patients With Ischemic Cardiomyopathy","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2026-01-30","conditions":"Heart Failure With Reduced Ejection Fraction, Coronary Artery Disease","enrollment":654},{"nctId":"NCT07238764","phase":"NA","title":"OCT-based DAPT Cessation in HBR Patients","status":"COMPLETED","sponsor":"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health","startDate":"2022-06-12","conditions":"High Bleeding Risk Patients, DAPT(Dual Antiplatelet Therapy), Coronary Artery Disease","enrollment":40},{"nctId":"NCT06090890","phase":"PHASE4","title":"Anti-inflammatory Therapy for Recurrent In-stent Restenosis","status":"RECRUITING","sponsor":"Fu Wai Hospital, Beijing, China","startDate":"2023-10-30","conditions":"In-stent Restenosis","enrollment":252},{"nctId":"NCT07068490","phase":"","title":"Impact of Potassium Competitive Acid Blockers After Percutaneous Coronary Intervention for Efficacy and Safety Outcome: Target Trial Emulation Study.","status":"RECRUITING","sponsor":"Samsung Medical Center","startDate":"2024-10-22","conditions":"Coronary Artery Disease","enrollment":100000},{"nctId":"NCT05122780","phase":"PHASE4","title":"Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-07-01","conditions":"Myocardial Infarction With Non-Obstructive Coronary Arteries","enrollment":120},{"nctId":"NCT05978726","phase":"","title":"Ticagrelor Versus Clopidogrel for CMD in Patients With AMI: A Retrospective Study Based on the Angio-IMR","status":"COMPLETED","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2017-07-01","conditions":"Coronary Heart Disease","enrollment":325},{"nctId":"NCT03008083","phase":"PHASE4","title":"Comparison Three vs Twelve Months of Dual Anti-Platelet Therapy After Stent Implantation","status":"UNKNOWN","sponsor":"Shanghai MicroPort Medical (Group) Co., Ltd.","startDate":"2019-01-10","conditions":"Drug-Eluting Stents, Percutaneous Coronary Intervention","enrollment":2446},{"nctId":"NCT02974777","phase":"PHASE4","title":"The IDEAL-PCI Extended Registry","status":"WITHDRAWN","sponsor":"Kaiser Franz Josef Hospital","startDate":"","conditions":"Coronary Arterioscleroses, Platelet Dysfunction Due to Drugs","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"DAPT on-target","genericName":"DAPT on-target","companyName":"Kaiser Franz Josef Hospital","companyId":"kaiser-franz-josef-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"DAPT (dual antiplatelet therapy) on-target inhibits platelet aggregation through simultaneous blockade of multiple platelet activation pathways to prevent thrombotic events. Used for Acute coronary syndrome (ACS) with percutaneous coronary intervention (PCI) and stent placement, Secondary prevention of stent thrombosis and recurrent myocardial infarction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}